Takara BioFRA:TF2 74 Days Payable is 25.05 as of Mar. 2026, which is 37% below its 10-year median of 39.85. GuruFocus rates FRA:TF2 with a GF Score™ of 74/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 705 Biotechnology companies, Takara Bio ranks worse than 84.4% on this metric.
Takara Bio's average Accounts Payable for the
three
months ended in Mar. 2026 was €8.7 Mil. Takara Bio's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €31.6 Mil.
Hence, Takara Bio's Days Payable for the
three
months ended in Mar. 2026 was 25.05.
The historical rank and industry rank for Takara Bio's Days Payable or its related term are showing as below:
FRA:TF2'
s Days Payable Range Over the Past 10 Years
Min: 23.41 Med: 39.85 Max: 53.39
Current: 26.07
During the past 13 years, Takara Bio's highest Days Payable was 53.39. The lowest was 23.41. And the median was 39.85.
FRA:TF2's Days Payable is ranked worse than 84.4% of 705
companies
in the Biotechnology industry
Industry Median: 113.36
vs FRA:TF2: 26.07
Takara Bio's Days Payable
declined
from Mar. 2025 (35.24) to Mar. 2026 (25.05).
It may suggest that Takara Bioaccelerated paying its suppliers.
Takara Bio Days Payable Related Terms
Takara Bio Days Payable Historical Data
* Premium members only.
The historical data trend for Takara Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Takara Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where Takara Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Takara Bio's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takara Bio (FRA:TF2) has a Days Payable of 25.05 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Takara Bio and its competitors. This is 37% below median its historical median of 39.85. Over the past decade, Takara Bio's Days Payable has ranged from 23.41 to 53.39. According to the industry distribution chart, Takara Bio ranks #595 out of 705 companies in the Biotechnology industry, placing it in the top 84.4%.
Is Takara Bio's Days Payable too high?
Takara Bio's current Days Payable of 25.05 is 37% below median its 10-year median of 39.85. Over the past 10 years, this metric has ranged from a low of 23.41 to a high of 53.39. The Biotechnology industry median Days Payable is 113.36. Takara Bio's value of 25.05 is 77.9% below this industry median. Based on the distribution chart, Takara Bio ranks #595 out of 705 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Takara Bio has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #595 out of 705 companies for Days Payable. This places Takara Bio in the lower half of its industry. The industry median Days Payable is 113.36. Takara Bio's value of 25.05 is 77.9% below this benchmark. Historically, Takara Bio's own Days Payable has ranged from 23.41 to 53.39 over the past decade. While the company's 10-year median is 39.85 vs. the industry median of 113.36, Takara Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takara Bio's current Days Payable of 25.05 is 77.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current Days Payable is 25.05, which is 37% below median its own 10-year median of 39.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €5.95 — trading 33.4% above its estimated fair value. The current Days Payable is 25.05, which is 37% below median its 10-year median of 39.85 and 77.9% below the Biotechnology industry median of 113.36. Takara Bio's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Days Payable is 25.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.4% above its estimated GF Value™ of €4.46.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
Days Payable: 25.05 (37% below median its 10-year median of 39.85)
GF Value™: €4.46 vs. price of €5.95 (33.4% above fair value)
Industry Position: 77.9% below the Biotechnology median (#595 of 705)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
74GF Score
Get the complete analysis for FRA:TF2
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
